McKesson Just Bought Its Way Into Drug Development
McKesson is spending $2.25 billion to buy Precision Medicine Group, a biomarker-driven CRO. It's the latest sign that pharma's biggest middleman wants to be much more than a pill delivery service.
The Pill Delivery Guy Wants a Seat in the Lab
For most of its history, McKesson has been the FedEx of pharmaceuticals. It moves pills from Point A to Point B, takes a thin margin, and repeats at massive scale. Not exactly thrilling stuff.
But on Tuesday, the $100+ billion distribution giant announced it's buying Precision Medicine Group for approximately $2.25 billion. And this isn't another warehouse deal. Precision Medicine is a contract research organization (CRO), which means it helps drugmakers design clinical trials, track biomarkers, run specialty labs, and ultimately get therapies to market. McKesson, in other words, just bought itself a ticket from the loading dock to the lab bench.
The business will be folded into McKesson's Oncology & Multispecialty segment after closing, subject to the usual regulatory approvals. No specific close date was announced.
What Exactly Did McKesson Just Buy?
Precision Medicine Group, founded in 2012 and headquartered in Bethesda, Maryland, is one of the more interesting mid-size players in clinical development. It operates through two main platforms: Precision for Medicine, which handles biomarker-driven clinical research, and Precision AQ, which covers commercialization services like market access, medical communications, and investor relations.
Think of it as a one-stop shop for biopharma companies that need help getting a targeted therapy from bench to bedside. The company runs more than 600 clinical trials, manages more than 30 million biospecimens, and operates five specialty labs across the U.S. and Europe. It employs more than 3,200 people in 20 countries.
For context on valuation: Blackstone bought a majority stake in Precision Medicine back in 2020 at a roughly $2.3 billion valuation. So McKesson is paying about the same price six years later, which is either a sign of disciplined buying or a reflection that growth hasn't exactly been explosive.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Why a Distribution Giant Wants to Play Scientist
This deal makes a lot more sense when you zoom out and look at what McKesson has been doing for the last two years. The company isn't just dabbling in diversification; it's systematically moving up the value chain.
In August 2024, McKesson agreed to acquire roughly a 70% controlling stake in Florida Cancer Specialists' Core Ventures for about $2.49 billion, a deal that closed in June 2025. That gave McKesson deeper roots in community-based oncology care. A few months later, it completed an acquisition of an 80% interest in PRISM Vision Holdings, adding ophthalmology and retina management to its portfolio.
Meanwhile, McKesson has been pruning what it doesn't want. The company announced plans to spin off its Medical-Surgical Solutions segment entirely. The message is clear: commodity distribution is yesterday's game. Specialty care, oncology services, and clinical development are where the growth (and the margins) live.
Buying Precision Medicine is the logical next step in that playbook. It gives McKesson capabilities in biomarker intelligence, trial execution, companion diagnostics, and commercialization support, all of which are essential infrastructure for the precision oncology era.
The Quiet Arms Race Among Big Distributors
McKesson isn't the only distribution giant eyeing this transformation. Its two biggest competitors are running the same play, just with different targets.
Cencora (formerly AmerisourceBergen) expanded into retina specialty care by acquiring Retina Consultants of America. Cardinal Health bought Solaris Health, a urology management services organization, and moved into oncology practice management through Integrated Oncology Network.
All three companies are chasing the same thesis: specialty drugs, biologics, and gene therapies are growing much faster than the traditional pill-shuffling business. The real money isn't in moving boxes anymore; it's in owning the relationships, data, and clinical infrastructure that precision medicines depend on to reach patients.
Precision Medicine gives McKesson something its competitors don't yet have, though: a full-service CRO with deep biomarker expertise. That's not just a clinical asset. It's a commercial one, because the same data and analytics that power clinical trials also inform launch strategy and market access.
What Wall Street Thinks (So Far)
Analyst reactions have been measured but mostly positive. Leerink analyst Michael Cherny reportedly viewed the deal as consistent with McKesson's existing portfolio. JPMorgan's Lisa Gill said it should strengthen McKesson's biopharma offerings.
The deal also doesn't break the bank. At $2.25 billion, it represents just over 2% of McKesson's market capitalization. Cherny specifically characterized it as something other than a "bet-the-farm" transaction. That's a polite way of saying investors shouldn't panic.
But the questions aren't trivial. Investors want to see how McKesson plans to generate synergies and scale Precision's capabilities within a distribution-centric culture. Integrating a research-oriented organization into a logistics company is like merging a jazz ensemble with a marching band: both make music, but the rhythms are very different.
The Bigger Picture: CROs Are Getting Swallowed
This deal also reflects a broader trend in the CRO market, which is consolidating fast. The global pharmaceutical CRO market hit an estimated $45.3 billion in 2025 and is projected to reach $83.3 billion by 2033. Mid-tier CROs are increasingly being absorbed by larger strategic buyers who want integrated platforms combining clinical operations, translational science, lab services, and AI-driven analytics.
The winners in this new landscape are the firms that can bundle biomarker discovery, patient selection, trial execution, and regulatory navigation into a single offering. Standalone CROs that only run trials without those wraparound services are becoming less competitive.
For Precision Medicine, getting acquired by McKesson could actually be a growth accelerator. McKesson's oncology network, provider relationships, and data assets (through its Ontada platform) could feed Precision's trial recruitment and commercialization engine in ways that a private-equity owner like Blackstone simply couldn't.
The Bottom Line
McKesson's acquisition of Precision Medicine Group isn't just a deal. It's a declaration. The company that built its empire moving pills is now betting billions that the future belongs to whoever controls the clinical and commercial infrastructure around precision therapies.
Whether McKesson can actually execute on that vision, blending logistics DNA with research-driven culture, is the $2.25 billion question. But one thing is certain: the line between drug distribution and drug development just got a whole lot blurrier.
Deals & M&A4 min read
The Biotech Investor That Got Caught Peeking at the Answer Key
A federal court found RA Capital and Avilar Therapeutics guilty of willfully stealing a trade secret from Yale, awarding $4 million to Biohaven and the university. The verdict could reshape how biotech investors handle confidential academic science forever.
